TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023.  The ...

Skin cancer is the most commonly diagnosed cancer in the United States, affecting one in five Americans during their lifetime. While basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

Spread the loveIn a groundbreaking study, researchers from Sweden have unveiled an artificial intelligence (AI) system capable of predicting the risk of melanoma years before it manifests. This ...

The dogs are detecting changes in volatile organic compounds — substances produced by the body when diseases like cancer are ...